Related Experiment Video
Updated: Oct 10, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Abstract:
In a phase I trial, the antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging response rates and manageable toxicity in patients with advanced/metastatic triple-negative breast cancer that has recurred after, or is resistant to, multiple therapies. Overall, 34% of patients experienced a complete or partial response.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023